# SAD and MAD Study With IV and SC Doses of ARGX-117

> **NCT04532125** · PHASE1 · COMPLETED · sponsor: **argenx** · enrollment: 110 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** ARGX-117
- **OTHER:** Placebo
- **BIOLOGICAL:** ARGX-117 + rHuPH20
- **OTHER:** placebo + rHuPH20
- **BIOLOGICAL:** ARGX-117 PH20 SC
- **OTHER:** Placebo PH20 SC

## Key facts

- **NCT ID:** NCT04532125
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-03
- **Primary completion:** 2022-08-26
- **Final completion:** 2022-08-26
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04532125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04532125, "SAD and MAD Study With IV and SC Doses of ARGX-117". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04532125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*